Close Menu

In an editorial, Nature announces that they will be introducing a creative commons license for the reuse of papers reporting full genome sequences. Under this license, non-commercial publishers may reuse the pdf and html versions of the article and other users may copy, distribute, and/or adapt the paper for non-commercial uses. This continues, the editors write, "[Nature's] drive to make papers as accessible as possible."

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.